Q4 25 EPS
$1.74
BEAT +10.05%
Est. $1.58
Q4 25 Revenue
$720.9M
BEAT +3.07%
Est. $699.4M
vs S&P Since Q4 25
-51.3%
TRAILING MARKET
VEEV -19.4% vs S&P +31.8%
Full Year 2025 Results
FY 25 EPS
$6.60
BEAT +2.29%
Est. $6.45
FY 25 Revenue
$2.75B
BEAT +0.82%
Est. $2.72B
Market Reaction
Did VEEV Beat Earnings? Q4 2025 Results
Veeva Systems capped fiscal year 2025 with an outstanding quarter, posting Q4 earnings per share of $1.74 against a consensus estimate of $1.58, a beat of 10.13%, while revenue of $720.89 million topped the $698.57 million estimate by 3.19% and grew … Read more Veeva Systems capped fiscal year 2025 with an outstanding quarter, posting Q4 earnings per share of $1.74 against a consensus estimate of $1.58, a beat of 10.13%, while revenue of $720.89 million topped the $698.57 million estimate by 3.19% and grew 14.3% year over year. The strongest driver behind the results was an acceleration in subscription services, which reached $608.58 million in the quarter, up 17% year over year, fueled by broad platform adoption across both Commercial and R&D Solutions. Quality Cloud added 41 new customers in the period, while one top 20 biopharma committed to a full Clinical Platform approach in what management described as one of Veeva's largest subscription orders ever. Non-GAAP operating margin expanded sharply to 42.7% from 37.9% a year ago, reflecting meaningful operating leverage. Looking ahead, Veeva guided full fiscal year 2026 revenues of $3.04 billion to $3.06 billion with non-GAAP diluted EPS of approximately $7.32, signaling continued confidence in double-digit growth as its Vault CRM Suite rollout broadens across life sciences.
Key Takeaways
- • Subscription services revenue growth of 17% year over year in Q4
- • Strong execution across both Commercial Solutions and R&D Solutions
- • Operating leverage driving non-GAAP operating margin expansion to 42.7% from 37.9%
- • Deepened strategic partnerships across all customer segments from top 20 biopharmas to emerging biotechs
VEEV YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
VEEV Revenue by Segment
With YoY comparisons, source: SEC Filings
“It was an outstanding quarter and year of execution and innovation in software, data, and business consulting. These advances set us up for the significant opportunity ahead to help life sciences bring better treatments to more patients, with greater speed and efficiency. I am excited to see what we can accomplish with our customers and the Veeva team in the coming years.”
— Peter Gassner, Q4 2025 Earnings Press Release
VEEV Earnings Trends
VEEV vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
VEEV EPS Trend
Earnings per share: estimate vs actual
VEEV Revenue Trend
Quarterly revenue: estimate vs actual
VEEV Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 27 BEAT | $2.14 | $2.24 | +4.91% | $882.9M | +2.94% |
| Q4 26 BEAT FY | $1.94 | $2.06 | +6.45% | $836.0M | +3.08% |
| FY Full Year | $7.94 | $8.10 | +2.02% | $3.20B | +0.76% |
| Q3 26 BEAT | $1.95 | $2.04 | +4.55% | $811.2M | +2.35% |
| Q2 26 BEAT | $1.90 | $1.99 | +4.73% | $789.1M | +2.65% |
| Q1 26 BEAT | $1.74 | $1.97 | +12.98% | $759.0M | +4.22% |
| Q4 25 BEAT FY | $1.58 | $1.74 | +10.05% | $720.9M | +3.07% |
| FY Full Year | $6.45 | $6.60 | +2.29% | $2.75B | +0.82% |